Merck KGaA, Darmstadt, Germany, a leading science and technology company, announces that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck KGaA, Darmstadt, Germany’s revenues and is expected to be accretive to the company’s earnings per share pre (EPS pre) by 2027.
Read the full article: Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of Its Healthcare Business //
Source: https://www.businesswire.com/news/home/20250630369209/en/Merck-KGaA-Darmstadt-Germany-Completes-Acquisition-of-SpringWorks-Therapeutics-to-Accelerate-Sustainable-Growth-of-its-Healthcare-Business